These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38185015)

  • 1. Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity.
    Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB
    J Neurol Sci; 2024 Feb; 457():122862. PubMed ID: 38185015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy.
    Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):243-249. PubMed ID: 35879821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
    Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB
    JAMA Netw Open; 2024 Aug; 7(8):e2424139. PubMed ID: 39120903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes.
    Mahfouz FM; Li T; Joda M; Harrison M; Horvath LG; Grimison P; King T; Marx G; Goldstein D; Park SB
    Support Care Cancer; 2023 Dec; 32(1):46. PubMed ID: 38117349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes.
    Kandula T; Farrar MA; Cohn RJ; Mizrahi D; Carey K; Johnston K; Kiernan MC; Krishnan AV; Park SB
    JAMA Neurol; 2018 Aug; 75(8):980-988. PubMed ID: 29799906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB
    J Natl Compr Canc Netw; 2019 Aug; 17(8):949-955. PubMed ID: 31390588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH.
    Streckmann F; Hess V; Bloch W; Décard BF; Ritzmann R; Lehmann HC; Balke M; Koliamitra C; Oschwald V; Elter T; Zahner L; Donath L; Roth R; Faude O
    BMJ Open; 2019 Apr; 9(4):e024467. PubMed ID: 31023750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.
    Timmins HC; Li T; Goldstein D; Trinh T; Mizrahi D; Harrison M; Horvath LG; Friedlander M; Kiernan MC; Park SB
    J Cancer Surviv; 2022 Apr; 16(2):223-232. PubMed ID: 33641031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
    Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
    BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.
    Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB
    J Natl Compr Canc Netw; 2021 Jul; 19(7):821-828. PubMed ID: 34340206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.
    McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB
    J Cancer Surviv; 2019 Aug; 13(4):495-502. PubMed ID: 31172429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients.
    Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D
    Clin Auton Res; 2022 Dec; 32(6):497-506. PubMed ID: 36129622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity.
    Mahfouz FM; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Marx G; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2024 Feb; 22(2):108-116. PubMed ID: 38364373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
    Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
    Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience.
    Velasco R; Besora S; Argyriou AA; Santos C; Sala R; Izquierdo C; Simó M; Gil-Gil M; Pardo B; Jiménez L; Clapés V; Calvo M; Palmero R; Bruna J
    Anticancer Drugs; 2021 Jan; 32(1):88-94. PubMed ID: 33332891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced peripheral neurotoxicity.
    Cavaletti G; Marmiroli P
    Curr Opin Neurol; 2015 Oct; 28(5):500-7. PubMed ID: 26197027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical impairments, sensory disturbance, and functional ability in a cancer patient with and without chemotherapy-induced peripheral neuropathy symptoms.
    Rattanakrong N; Promma N; Saraboon C; Waongenngarm P
    Support Care Cancer; 2022 Jun; 30(6):5055-5062. PubMed ID: 35217909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.